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Adeno-associated viral vectors are showing great promise as gene therapy vectors for a wide 
range of retinal disorders. To date, evaluation of therapeutic approaches has depended almost 
exclusively on the use of animal models. With recent advances in human stem cell technology, 
stem-cell derived retina now offers the possibility to assess efficacy in human organoids in vitro. 
Here we test 6 AAV serotypes (AAV2/2, AAV2/9, AAV2/8, AAV2/8T(Y733F), AAV2/5 and 
ShH10) to determine their efficiency in transducing mouse and human pluripotent stem cell 
(PSC)-derived RPE and photoreceptor cells in vitro. All the serotypes tested were capable of 
transducing RPE and photoreceptor cells in vitro. AAV ShH10 and AAV2/5 are the most efficient 
vectors at transducing both mouse and human RPE, while AAV2/8 and ShH10 achieved 
similarly robust transduction of human ESC-derived cone photoreceptors. Furthermore, we show 
that hESC-derived photoreceptors can be used to establish promoter specificity in human cells 
in vitro. The results of this study will aid capsid selection and vector design for pre-clinical 
evaluation of gene therapy approaches, such as gene editing, that require the use of human 
cells and tissues. 
 





AAV vectors have been used in a number of clinical trials of retinal gene therapy (for recent 
review see Auricchio et al.1). These include seminal trials of therapies to treat childhood 
blindness caused by RPE65 related Leber congenital amaurosis (LCA)2-6. A number of different 
AAV vector pseudotypes exist that display distinct transduction profiles, which may be used to 
deliver the transgene of interest to specific cell types. Conventionally, mouse7 and large animal 
models, including dogs8,9, pigs10-12 and primates13,14 have been used to evaluate AAV specificity 
and efficiency for transducing photoreceptors and RPE in vivo. The in vivo results consistently 
show greater photoreceptor transduction efficiency by serotypes AAV2/5, 2/8 and 2/9, compared 
with the archetypal AAV2/2 vector. Recently, screening for tropism and infectivity of human 
retinal cells has also been performed in ex vivo human retinal explants, although the results 
appear to be highly variable between individual explants15-17.  
 
The availability of pluripotent stem cells (PSC) that can be effectively differentiated into 3D 
retinal organoids has brought many new opportunities for accelerating the development of novel 
therapies for wide range of retinal conditions, including inherited retinal dystrophies caused by 
defects in either photoreceptors or the retinal pigment epithelium (RPE). Numerous reports have 
described the differentiation of both mouse and human pluripotent stem cells into photoreceptors 
and RPE, for transplantation18-25 and in vitro disease modeling studies, using patient-derived 
induced pluripotent stem cells (iPSCs)26-29. The combined use of relatively new stem cell 
technologies, together with the more established use of recombinant adeno-associated viral 
(AAV) vectors for gene therapy represents a unique opportunity for advancing our ability to 
understand and treat inherited retinal disorders.  
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A growing number of studies are utilizing PSC-derived retinal organoids and efficient gene 
transfer to these tissues is of increasing interest. We have previously observed that AAV vectors 
are more effective at mediating gene transfer than either lentiviral vectors or physical methods 
such as transfection or electroporation and have therefore previously used AAV vectors to mark 
mouse and human PSC-derived photoreceptor precursors in order to isolate and purify them for 
use in transplantation studies25,30,31.  Human PSC-derived retinal organoids provide access to 
large numbers of normal and diseased samples and also offer a new platform to evaluate gene 
correction by gene therapy specifically in human retinal cells. The precise modification of the 
genome can be achieved by well-described gene editing technologies, such as zinc fingers, 
TALENS and CRISPR/Cas932,33. The in vivo delivery of these editing tools to the mouse retina 
using AAV has now been demonstrated in a number of recent studies (for review see34). 
However, as a prelude to in vivo gene editing, double strand breaks efficiency, cutting specificity, 
and efficiency of gene integration, when a donor DNA is used, needs to be tested first in cells in 
vitro.  Whilst various cells lines can be used, mouse and human retinal organoids provide more 
appropriate tools to evaluate gene editing than primary cell lines. Furthermore, in the case of 
patient-derived human organoids, these provide unlimited number of diseased cells to develop 
and test the most efficient gene correction technology. Whilst AAV vectors are promising tools 
for mediating gene editing in retinal organoids, it is first necessary to establish which AAV 
serotypes most efficiently transduce these tissues in vitro.  This study therefore assesses the 
tropism of AAV vectors in stem cell-derived retinal organoids. We sought to determine the 
relative transduction efficiencies and toxicities of six AAV serotypes (AAV2/9, AAV2/8, 
AAV2/8T(Y733F), AAV2/5, AAV2/2 and ShH10(Y445F)) in mouse and human PSC-derived 
photoreceptor and RPE cells. These 6 serotypes were chosen for comparison in vitro 
because of their widespread use in vivo. AAV2/8, AAV2/2 and AAV2/5 have been used 
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in ocular gene therapy trials, whilst AAV2/9 and the two engineered capsids, ShH10 and 
AAV2/8T(Y733F), mediate particularly efficient in vivo transduction. 
 
 
Materials and Methods 
 
Mouse ESC retinal differentiation culture 
A CCE mouse ES cell line (129/SvEv; a kind gift of Professor E. Robertson) was maintained as 
previously described35. For 3D retinal differentiation, 3x104 dissociated ES cells were re-
suspended per ml of differentiation medium (GMEM containing 1.5% KSR, 0.1mM NEAA, 1mM 
pyruvate, 0.1mM 2-mercaptoethanol), plated into 96 well low-binding (Corning) plates and 
incubated at 37oC, 5% CO2. Embryoid body cell aggregates (EBs) formed within 24 hrs, on day 
1 of culture, growth factor reduced Matrigel (GIBCO) was added to each well to give a final 
concentration of 2%. For whole EB retinal differentiation towards photoreceptor cell fate, EBs 
were transferred into retinal maturation medium (DMEM/F12 Glutamax containing N2 
supplement and Pen/strep) at day 9, plated in low-binding plates at a density of 6 EBs/cm2 and 
incubated at 37oC, 5% CO2. The media was changed every 2-3 days, with the addition of 1mM 
Taurine (Sigma) and 500nM retinoic acid (Sigma) from day 14 of culture onwards. For whole EB 
retinal differentiation towards RPE cell fate, EBs were treated with 500nM working solution of 6-
bromoindirubin-3'-oxime, BIO (Sigma), from day 5 onwards. For monolayer cultures of RPE 
pigmented regions of the BIO-treated EBs were manually dissected with a 21G needle and 
platted these on laminin coated chamber slides. 
 
Human ESC maintenance and retinal differentiation culture 
The human embryonic and iPS stem cell lines (H9 and IRM90-4 from Wicell) were maintained 
on feeder free conditions on E8 and geltrex coated 6 well plates. RPE differentiation protocol 
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was adapted from previous published protocols19,36. Briefly, hPSCs were dissociated using a 
dispase and collagenase solution. PSC clumps were collected and re-suspended in E8 media. 
The cell clumps were then transferred to a low-binding 10 cm plate to form floating EBs. 
Differentiation media was changed to EB media (DMEM/F12 (1:1), Knockout serum 
replacement, MEM non-essential amino acids, L glutamine, 2-Mercaptoethanol, Pen/Strep) 
containing 100ng/ml of dorsomorphin (BMP inhibitor) and 100ng/ml of XAV939 (DKK1-Wnt 
inhibitor) from day 2 to 3 of culture. From day 4 of culture media was changed to neural 
induction media (Advanced DMEM/F12, MEM non-essential amino acids, N2, Heparin and 
Pen/Strep). On day 7 EBs were platted on laminin for growth as adherent cultures. From day 15 
media was changed to retinal maturation media (DMEM, F12, B27 without retinoic acid and 
Pen/Strep) containing 50 ng/ml of Activin A (R&D) was added from day 18 to 40. Islands of 
pigmented RPE appeared between day 40-60 and these regions were manually dissected for 
further expansion and quantification on laminin-coated wells. 
 
For retinal neuroepithelia differentiation we used a previously described protocol25. Briefly, 
human PSCs were maintained until confluent when media without FGF was added to cultures 
for two days. Proneural induction media (Advanced DMEM/F12, MEM non-essential amino 
acids, N2 Supplement, 100mM Glutamine and Pen/Strep) was added until optic vesicles were 
observed. Vesicles were manually excised and kept in 96 well plates in retinal differentiation 
media (DMEM, F12, Pen/Strep and B27 without retinoic acid) and at 6 weeks of differentiation 
medium was supplemented with FBS, taurine and glutamax and at 10 weeks RA was added. 
 
Production of recombinant AAV serotypes and in vitro transduction analysis 
A pD10/CMV promoter-GFP, construct containing AAV-2 inverted terminal repeat (ITR) was 
used to generate AAV2/9, AAV2/8, AAV2/8(Y733F), AAV2/5, AAV2/2 and ShH10(Y445F) 
CMV.GFP viruses. A pD10/Rhodopsin promoter-GFP and a pD10/2.1PRM/L-opsin promoter-
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GFP was used to generate viruses.  Recombinant AAV2/2 serotype particles were produced 
through a previously described triple transient transfection method HEK293T cells(37). AAV2/8, 
AAV2/8(Y733F), AAV2/5, AAV2/2 and ShH10(Y445F) serotypes were bound to an AVB 
Sepharose column (GE Healthcare), and eluted with 50 mM Glycine pH2.7 into 1 M Tris pH 8.8. 
AAV2/9 was purified by size separation on a Sephacryl S300 column, followed by anion 
exchange chromatography using a POROS 50 HQ column, eluting the vector in 20 mM Bis-Tris 
propane, 20 mM Trizma Base and 0.24 M NaCl pH9. Vectors were washed in 1 × PBS and 
concentrated to a volume of 100–150 µl using Vivaspin 4 (10 kDa) concentrators. Viral genome 
titres were determined by quantitative real-time PCR using a probe-based assay binding the 
SV40 poly-adenylation signal. Amplicon-based standard series of known amounts were used for 
sample interpolation. Final titres were expressed as vg/mL.  
 
SV40 Forward primer: 5’-AGCAATAGCATCACAAATTTCACAA-3’. 
SV40 Reverse primer: 5’-AGATACATTGATGAGTTTGGACAAAC-3’.  
SV40 Probe: FAM-5’-AGCATTTTTTTCACTGCATTCTAGTTGTGGTTTGTC-3’-TAMRA. 
 
The same number of EBs or RPE cells per well were used in all experiments (approximately 
1.5x 106 EB cells and 2x106 RPE cells per well) and infected with 1.2x1011 viral particles per well 
in appropriated retinal medium. Estimated gMOI of 8000 and 6000. 
 
Flow cytometry analysis 
For flow cytometry experiments, mouse whole EBs (wEBs) were dissociated at day 29 of culture 
into a single cell suspension using a modified protocol using reagents from the papain-based 
Neurosphere Dissociation Kit (Miltenyi Biotec). Cells were counted and resuspended in 1% 
Bovine Serum Albumin (in PBS) to a concentration of 1x107 cells per mL, and staining was 
performed with 100µL aliquots. For surface marker analysis, an antibody against mouse CD73 
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(APC-conjugated rat IgG1, clone TY/11.8, Miltenyi Biotec) was added at a 1:75 dilution and 
incubated for 30 minutes at 4oC. Cells were washed once in 1x Binding Buffer (eBioscience). For 
subsequent viability analysis, Annexin V-eFluor 450 (eBioscience) was added to samples at a 
1:20 dilution (in 1X Binding Buffer) and incubated for 15 minutes at room temperature. Cells 
were washed once in 1X Binding Buffer and resuspended in PBS. DRAQ7 (BloStatus) was then 
added to the samples at a final concentration of 50ng/ml for 5 minutes at room temperature 
before analysis.  
 
Cells were analysed using FlowJo software. Background fluorescence was measured using 
unstained cells and single-stained controls were used to set gating parameters between positive 
and negative populations. Small debris, cell fragments and aggregates were excluded from 
analysis on the basis of Annexin V and live-dead dye non-fluorescence (double negative 
population), followed by forward and side scatter (measuring cell size and granularity 
respectively). For cell surface marker analysis, dead cells were excluded from analysis on the 
basis of live-dead dye fluorescence as well. 
 
For cell sorting experiments FACS was performed on a BD Influx Cell SorterTM (BD 
Biosciences) fitted with a 200mW 488nm blue laser to excite GFP. GFP was collected using the 
488-530/40nm detector. A 70 micron nozzle at 30 psi was used and cells were collected on a 
1:1 FBS/ EBSS solution. 
 
Immunohistochemistry  
For wEBs and BIO-treated wEBs experiments titre matched viruses were added at day 22 of 
differentiation and wEBs were collected for immunohistochemistry analysis at day 29 of culture. 
For adherent cultures of RPE, viruses were added between day 20 and 22 and chamber slides 
were fixed 7 days later. Whole EBs and eye cups were fixed for 1 hour in 4% paraformaldehyde 
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(PFA) and embedded in OCT (RA Lamb). Cryosections were cut (18 µm thick) and all sections 
were collected for analysis. For immunohistochemistry, sections were blocked in 5% goat serum 
and 1% bovine serum albumin in PBS. Primary antibody (Supplementary Table 1) was 
incubated overnight at 4°C. Sections were incubated with secondary antibody for 2 hrs at RT, 
washed and counter-stained with DAPI. Alexa fluor 488, 546 and 633 secondary antibodies 
were used at a 1:500 dilution. 
 
Image acquisition  
Images were acquired by confocal microscopy (Leica DM5500Q). A series of XY optical 
sections, approximately 1.0µm apart, throughout the depth of the section were taken and built 
into a stack to give a projection image. LAS AF image software was used.  
 
Statistical analysis 
All means are presented ± SD (standard deviation), unless otherwise stated; N, number of 
animals or independent experiments performed; n, number of eyes or EBs examined, where 
appropriate. For quantification assessment by Flow cytometry and cell counting of transduction 
efficiency, statistical analysis is based on at least three independent experiments. Statistical 
significance was assessed using Graphpad Prism 6 software and denoted as P<0.05= *, 
P<0.01= ** and P<0.001= ***. Appropriate statistical tests were applied including t-test; ANOVA 




AAV transduction of mouse PSC-retinal cells 
 
AAV transduction of mouse ESC-derived whole embryoid bodies (wEBs) 
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First, we sought to determine how efficiently we could transduce retinal organoids using AAV 
vectors. We have described previously the 3D-differentiation of retinal cells from mouse ESC-
derived (mESC) wEBs. These structures contain both neural and glial cells, as well as retinal 
neuroepithelium containing mostly photoreceptors and fewer less well-developed retinal 
interneurons (30). We tested six different AAV serotypes, each driving eGFP under the control of 
a CMV promoter. A schematic of the 3D differentiation and vector transduction protocol is shown 
in Fig. 1a. At day 22 of differentiation, titre-matched AAV vectors (1.2x1011 vg/well) were added 
to wEB cultures (6 wEBs in 0.3 mL medium) and the presence of GFP+ cells was assessed 7 
days later. The AAV serotypes exhibited different patterns of tropism in vitro (Figs. 1b-g). Low 
magnification images of wEB sections at day 29 of culture showed GFP+ cells not only in 
regions of retinal neuroepithelium (Fig. 1b, arrow head), but also in other regions of the wEBs 
(Fig. 1b, arrow). The number of GFP+ transduced cells was analysed by flow cytometry. The 
percentage of GFP+ cells was significantly higher (53% ± 8.7) following transduction by ShH10 
than by the other serotypes tested. AAV2/9 (16% ± 7.5), AAV2/8 (20% ± 4), AAV2/8T (16% ± 
1.3) and AAV2/5 (12% ± 5.3) serotypes provided similar transduction efficiency and AAV2/2 
transduced just 6% (± 2.6) of cells (Fig. 1h; p<0.001, ANOVA; n=3 independent differentiation 
cultures and Fig. S1a,b). Furthermore, ShH10.CMV.GFP+ labeled cells were not only more 
numerous, but also had a stronger and brighter GFP expression (Fig. S1c for normalized MFI 
(median fluorescence intensity) fold-values). Using a high vector titre can be toxic to target 
cells38 and thus it is also important to establish cell viability following transduction. To do this, we 
quantified by flow cytometry the percentage of early and late apoptotic (Live dead-/AnnexinV+ 
and Live dead+/AnnexinV+, respectively), necrotic (Live dead+/AnnexinV-) and live cells (Live 
dead-/AnnexinV-) in cultures transduced with each of the different vectors. No significant 
differences in cell viability were noted, regardless of the serotype used (Fig. S1d).  
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Targeting photoreceptor cells with AAV vectors is of particular interest as these cells contain the 
primary defect in the majority of retinal degenerations. We therefore investigated the ability of 
the six serotypes to transduce mESC-derived photoreceptors specifically. We demonstrated 
previously that, similar to photoreceptors from the postnatal retina39,40 mESC-derived 
photoreceptors express a CD73 surface marker41. The percentage of CD73+ photoreceptor cells 
did not vary significantly between the different transduced cultures (Fig. 1i). However, the 
number of CD73+/CMV.GFP+ photoreceptor cells was significantly greater when cells were 
transduced with the ShH10 (24% ± 10.5%), compared with any of the other five serotypes (Fig. 
1i ANOVA, p < 0.0001; n=3 independent differentiations and Fig. S2a-c). Furthermore, no 
significant difference in the number of viable CMV.GFP+/CD73+ photoreceptors was detected 
between any of the six serotypes (Fig. S2d).  
 
ShH10 has been previously reported to specifically target astrocytes and Müller Glia following 
intravitreal (IV) injections42. We performed IV injections of the six CMV.GFP viruses into wild-
type post-natal day 6 (P6) pups, a similar stage to days 22-24 of differentiation, to assess the 
potential of these viruses to transduce different cell types in the postnatal neural retina (Fig. S3). 
Similar to previous studies42, we found that ShH10.CMV.GFP specifically transduces astrocytes 
and Müller glia following IV injections in vivo (Fig. S3f). However, immunohistochemistry 
analysis of ESC-derived wEBs transduced with ShH10.CMV.GFP demonstrated that 
neuroepithelium regions contained not only CRALBP+/GFP+ Müller glia cells but also many 
Recoverin+/GFP+ photoreceptors (Fig. S4). This is most likely due to increased viral vector 
accessibility in vitro. In the 3D wEB cultures, the presumptive inner nuclear layer (INL) is thinner, 
when compared with the postnatal retina, and these structures may lack astrocytes and the 
inner limiting membrane (ILM), both present at the vitreal surface of the postnatal retina. Our 
results demonstrate that ShH10 vectors are able to mediate significantly improved transduction 
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of mouse ESC-derived cells, including photoreceptors, compared with the other serotypes 
tested.  
 
AAV transduction of mouse ESC-derived rods and cones using cell-specific promoters 
To address questions of retinal and photoreceptor development using mouse ESC derived-
retinal organoids it is often necessary to target rod and/or cone photoreceptor cells specifically. 
To determine the transduction efficiency of rods and cones in vitro, we used either a bovine 
Rhodopsin promoter43 to obtain rod-specific expression  or a human L-opsin cone promoter  
(PR2.1opsin.GFP)44 to obtain cone-specific expression. We compared the transduction 
efficiency of an AAV2/9 vector with ShH10. Both AAV2/9.Rhop.GFP and ShH10.Rhop.GFP 
robustly and specifically labelled rod photoreceptors in 3D cultures, as demonstrated by GFP co-
localisation with the rod-specific protein Rhodopsin (Fig. 2a). In our mouse 3D retinal organoid 
cultures we do not observe M/L opsin positive cones31. However, subretinal injection of 
AAV2/8.PR2.1opsin.GFP virus into the mouse adult WT retina results in labeling of S cones, as 
well as M/L cones (Fig. S5). We therefore examined the efficiency of AAV2/9 and 
ShH10.PR2.1opsin.GFP transduction of S cones by co-localisation with S-opsin (blue opsin) 
(Fig. 2b). In wEBs transduced with either vector, GFP fluorescence co-localised with S-opsin 
staining. The percentage of Rhop.GFP+ rods and PR2.1opsin.GFP+ cones was significantly 
higher in wEBs transduced with ShH10 (24% ± 6.8 and 7% ± 1.3, respectively), compared with 
AAV2/9 (17% ± 5.0 and 4% ± 1.0, respectively) (Fig. 2c and Fig. S6; Unpaired t-test; rods p< 
0.05, n=9; cones p< 0.01, n=4 independent differentiations). No significant differences in viability 
were detected between any of the vectors tested (Fig. 2d).   
 
AAV transduction of mouse ESC-derived RPE 
To investigate the tropism of AAV serotypes with respect to mESC-derived RPE. We used a 3D 
suspension differentiation protocol where the Wnt agonist BIO was added from day 5 of culture. 
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A schematic of RPE differentiation is shown in Fig. 3a. Using this method, neuroepithelia that 
under non-BIO control conditions20 would normally generate thick neuroepithelium of retinal 
origin and a small number of pigmented RPE cells (Fig. 3b, black and white arrows, 
respectively), instead differentiate exclusively into thin, convoluted RPE layers (Fig. 3b, white 
arrows). First, we analysed the ability of the six AAV serotypes to transduce RPE derived from 
BIO-treated wEBs cultured in suspension. Sections of BIO-treated wEBs, positive for the early 
RPE marker Mitf, demonstrated the presence of CMV.GFP+ pigmented cells in all six serotypes 
tested (Fig. 3c). To quantify the proportion of RPE cells transduced, RPE regions were manually 
dissected from BIO-treated wEBs at day 14 of culture and plated to form adherent RPE 
monolayers that were positive for actin-label phalloidin and demonstrated the typical 
cobblestone-like RPE cell morphology (Fig. 3d). RPE monolayers were then transduced and the 
percentage of GFP+ RPE cells was quantified by manual cell counting. ShH10 and AAV2/5 
achieved similar levels of transduction, with around 70% of RPE cells being GFP+ (71% ± 11.2 
and 71% ± 26, respectively). These two serotypes were significantly more efficient at 
transducing mESC-derived RPE compared with the other 4 serotypes tested (Fig. 3e; p<0.001, 
ANOVA; n=3 independent differentiations). 
 
AAV transduction of human PSC-retinal cells  
 
AAV transduction of human PSC-derived RPE 
Pluripotent stem cells provide a renewable source of human RPE cells that can be used to study 
normal and disease mechanisms in vitro. Patient-derived iPSC-derived RPE cells offer a disease 
modelling platform that may allow the development of new treatments. Here, to assess which 
AAV serotypes most efficiently transduce human pluripotent stem cell (hPSC)-derived RPE in 
vitro, we differentiated human ES and iPS cells into RPE using a previously described 
protocol19,36. A schematic of the differentiation and virus infection protocol is shown in Figure 4a. 
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Titre-matched vectors were added between days 50-60 of culture and the number of GFP+ RPE 
cells was quantified as before, 7 days following addition of vector. Similar to mouse ESC-derived 
RPE, hPSC-derived RPE cultures formed typical pigmented and polygonal adherent cultures 
that expressed phalloidin (Fig. 4b). All serotypes were able to transduce adherent cultures of 
hPSC-derived RPE in vitro, albeit with different efficiencies. The proportion of ShH10 CMV.GFP-
transduced hPSC-derived RPE (76% ± 30) was significantly greater than for AAV2/9 (6% ± 3), 
AAV2/8 (6% ± 6), AAV2/8T (3% ± 2) and AAV2/2 (11% ± 6), but not compared with AAV2/5 
(37%± 18) (Fig. 4c; p< 0.01, ANOVA; n=3 independent differentiations). Usually, hPSC-derived 
RPE fields are picked manually from a heterogeneous population of retinal cells and as a result 
the final population is not always composed entirely of RPE cells. Therefore, to ensure specific 
targeting of RPE cells in vitro, specific promoters are needed. We have previously described that 
an optimised RPE65 human promoter can drive GFP expression in hPSC-derived RPE cells45. 
Here, we assessed if the same was true for the well-described human vitelliform macular 
dystrophy 2 (VMD2) promoter. We found that this promoter can also be used to target RPE in 
vitro and the percentage of GFP+ RPE cells transduced with the ShH10.VMD2.GFP (79% ± 5%) 
was not significantly different from cells transduced with ShH10.CMV.GFP (92% ± 8%) (Fig. 4d; 
ANOVA; n=3 independent differentiations). Furthermore, despite greater levels of GFP 
expression present in RPE cells transduced with vector containing a CMV promoter than in cells 
transduced with vector containing the RPE-specific VMD2 promoter, no differences in the 
viability of the cells were observed (Fig. 4e). Our results demonstrate that AAV vectors can 
readily transduce human RPE cells in vitro, with ShH10 and AAV2/5 performing significantly 
better than other commonly used serotypes. 
 
AAV transduction of human ESC-derived retinal organoids and photoreceptors 
A number of protocols have been reported for the differentiation of hPSCs into retinal tissues 
and cell types. We have adapted previously described protocols24,46 to generate retinal 
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neuroepithelia containing a layered neuroretina, including photoreceptors that exhibit 
rudimentary outer segments and synaptic structures25. A schematic of photoreceptor 
differentiation and virus infection protocol is shown in Fig. 5a. Briefly, human ESCs were kept in 
maintenance conditions to confluence, before adding FGF negative medium. Islands of 
pigmented RPE were observed 3-4 weeks later and continuous retinal neuroepithelium vesicles 
surrounded by RPE were observed from 4-7 weeks of culture.  These retinal vesicles were then 
excised from the 2D cultures and cultured further in suspension. We sought to establish the 
most efficient AAV serotype to transduce hESC-derived photoreceptors in vitro by testing the 
same six vectors described above. Titre matched CMV.GFP AAV vectors were added to hESC-
derived organoids at 13 weeks of culture and analysed for the presence of GFP+ 2 weeks later. 
All six vectors were able to transduce hESC-derived retinal vesicles. A low magnification image 
of an AAV2/8.CMV.GFP transduced vesicle shows a number of GFP+ cells within the vesicle 
(Fig. S7a,a’). Strikingly, however, none of these appeared to be photoreceptors, as identified by 
co-staining for RECOVERIN (Fig. 5b-h; n=3 independent experiments N>18 vesicles). This was 
the case for all six serotypes, including ShH10, which was able to transduce mouse mESC-
derived photoreceptors with very high efficiency. However, when viral transduction was 
performed 4 weeks later (17 weeks) CMV.GFP+/ RECOVERIN+ photoreceptors were observed 
in the ONL–like region (Fig. 5i-m). In organoids transduced with ShH10.CMV.GFP, other retinal 
cells, possibly Müller glia, were also GFP+ (Fig.5l). Flow cytometric analysis of hESC-derived 
organoids demonstrated equivalent transduction using AAV2/2 and ShH10 (19% ± 3 and 21% ± 
4, respectively), which were significantly greater than all the other vectors tested (Fig. 5n; 4% ± 
3 AAV2/9, 4% ± 3 AAV2/8, 5.5% ± 3 AAV2/8T, 4% ± 2.5% AAV2/5; P < 0.001, ANOVA; n=3 
independent differentiations). Therefore, the transduction efficiency of human PSC-derived 




Testing promoter specificity in human ESC-derived photoreceptors 
One requirement for many retinal gene therapy approaches is the specific targeting of 
photoreceptor cells that avoids off-target expression. There may also be a requirement to further 
discriminate between rod and cone photoreceptors. We therefore assessed the ability of our 
retinal organoid system to test the specificity of expression after AAV-mediated transduction of 
photoreceptor cells using cone- and rod-specific promoters.  Titre-matched vectors containing 
the cone-specific PR2.1opsin promoter driving eGFP were added between weeks 13-14 of 
culture and retinal organoids were collected two weeks later for immunohistochemistry and flow 
cytometry. Despite the addition of vectors at early stages in culture (13 weeks) we observed a 
number of GFP+ cells displaying typical cone morphology, with large inner segments and 
presumptive synaptic pedicles (Fig. 6a). ShH10.PR2.1.GFP+ cells co-expressed the cone-
specific protein, RXRγ, but not the rod photoreceptor-specific photopigment, RHODOPSIN (Fig. 
6b and c, respectively), demonstrating that all the transduced cells were indeed cone 
photoreceptors. To establish the transduction efficiency of the different serotypes and promoter 
specificity for the different cone photoreceptors subtypes. We tested four different AAV 
serotypes (ShH10, AAV2/9, AAV2/5 and AAV2/8) in hESC-derived organoids. GFP+ cells were 
observed in all transduced hESC-derived organoids and, in keeping with their normal position in 
the human outer nuclear layer (ONL), positive cells were mostly observed at the apical edge of 
the neuroepithelium. The efficiency of the ShH10.PR2.1 vector (15% ± 5) was similar to 
AAV2/8.PR2.1 vector (13% ± 2), and was significantly greater than AAV2/9 (3% ± 1), AAV2/2 
(2% ± 1) or AAV2/5 (2% ± 1) capsids (Fig. 6d and Fig. S7; P < 0.001, ANOVA; n=4 
independent differentiations). To determine in which cone photoreceptor subtypes the PR2.1 
promoter is active, we checked for co-localisation of GFP with red and green (L+M) opsins (M/L 
OPSIN) and blue opsin (S-OPSIN). Co-localisation of M-OPSIN and GFP+ cells was observed in 
the neuroepithelium (Fig. 6e, arrow). Co-localisation of GFP+ and S-OPSIN cones was also 
observed, but only in a small proportion of the S cones. These PR2.1opsin.GFP+/S-OPSIN+ 
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cones were observed only in ShH10 and AAV2/8 transduced organoids, but not in AAV2/9, 
AAV2/2 and AAV2/5 transduced organoids (Fig. 6f, arrow). Next, to test if a previously described 
human Rhodopsin promoter47 is active and drives expression of GFP in PSC-derived rod 
photoreceptors we used an ShH10 capsid (ShH10.hRho.GFP). Similar to serotypes bearing the 
CMV promoter, no GFP+ cells were observed following transduction at 13 weeks, but when 
administered at 17 weeks in culture, this vector readily transduced rod photoreceptors as 
observed by widespread GFP expression and co-localization with the rod specific marker, α-Rod 
Transducin (GNAT1) (Fig. 6g, g’). Finally, we also observed photoreceptor-specific labelling 
when using an ShH10 vector containing a human Rhodopsin Kinase promoter fragment48 
(ShH10.hRK.GFP). Despite the sporadic labelling at the time point tested (17 weeks), our results 
confirm that this promoter fragment is active in both ARRESTIN3+ human cone (Fig. 6h, h’) and 
GNAT1+ rod photoreceptors (Fig. 6i,I’) and is therefore an appropriate promoter for gene 
therapies targeting both types of photoreceptors. 
 
The results presented here confirm that the PR2.1.opsin and hRhodopsin promoters mediate 
robust and specific expression in human cone and rod photoreceptors, respectively. The PR2.1 
promoter is active predominantly in M/L-cones, but also in some blue S-cones when 
transduction efficiency is high. Again, the ShH10 capsid was the most efficient serotype for the 
transduction of human cone photoreceptors in vitro. Surprisingly, the AAV2/8 serotype, which 
transduced mouse ES-derived photoreceptors poorly, transduced human ESC-derived cones 
efficiently in vitro. Most importantly, our results demonstrate that cone photoreceptors can be 
transduced at early time points in culture, whilst GFP+ rod photoreceptors were only observed 





Numerous studies have demonstrated successful gene supplementation to the RPE and 
photoreceptor cells via AAV vectors in animal models49 and the translation of some of these 
findings into clinical trials has established the feasibility of AAV ocular gene therapy5,6,50,51. A 
number of parameters must be fulfilled by preclinical studies prior to starting a gene therapy 
clinical trial. These include establishing vector tropism, vector transduction efficiency, expression 
of the transgene specifically in the target cells, safety and finally rescue of a disease phenotype. 
These provide proof-of-concept, and are usually performed in mouse and larger animal models. 
In the last few years, with the advent of efficient gene editing techniques, there may also a 
requirement for additional pre-clinical proof-of-concept studies involving human retinal cells. 
Stem cell technology has evolved rapidly in the past decade and is now able to provide human 
retinal organoids for studying development and disease in vitro and for the development of 
therapeutic approaches involving gene editing. In order to facilitate the development of such 
therapies we compared the efficacy of various AAV viral vectors in mouse and human stem cell 
derived RPE and photoreceptor cells.  
 
Much of our understanding about AAV tropism has been established in the mouse retina, 
together with larger animals including pigs and dogs. To our knowledge, this is the first time the 
efficiency of AAV serotypes have been compared in stem cell-derived mouse and human retinal 
cells. We report a marked difference in transduction efficiency, dependent upon the serotype 
used. Overall, the ShH10 serotype, an AAV6 variant generated by directed evolution 
methodology42, performed superiorly compared with the other AAV serotypes tested. However, 
some serotypes performed similarly to ShH10, dependent on the cell type; AAV2/5 and AAV2/8 
were equivalent to ShH10 at transducing mouse and human RPE, and human cone 
photoreceptors, respectively. Although very useful to selectively target Müller glia in mice via 
intravitreal injections, our studies demonstrate that this serotype can also be used in vitro to 
target mouse and human ESC-derived photoreceptors and RPE with high efficiency. Our 
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findings underline the importance of selecting the appropriate AAV serotype for efficient 
transduction of the target cells for in vitro studies.  
 
Pluripotent stem cell-derived human retinal cells can also be used to test promoter specificity, 
which would otherwise be tested in non-human primates. Here we show that AAV vectors 
carrying GFP under the control of the CMV promoter drive robust expression in mouse ESC-
derived photoreceptors. Interestingly, the same vectors failed to drive expression following 
administration to 13-week-old human ESC-derived photoreceptors, whereas transduction of 17-
week-old neuroepithelia resulted in robust GFP expression in photoreceptors. This data is in 
agreement with recent reports demonstrating that the developmental stage of the retina 
influences AAV transduction efficiency in photoreceptor cells7. A recent study by Petit et al., 
(2017) suggested that outer segments are necessary for viral transduction of rod 
photoreceptors52. Indeed, our data supports these findings, as 13-week-old neuroepithelia 
contains photoreceptor inner segments but not outer segments (OS)-like structures, while the 
first rudimentary OS structures are observed from 16 weeks of development25. In contrast, 
transduction of cones by vectors carrying PR2.1opsin.GFP was observed even in early stages of 
culture. This is also consistent with the study by Petit et al. which showed that cone, but not rod 
photoreceptors, were efficiently transduced at early post-natal stages in mice52. These results 
show that care should be taken when assessing vectors in retinal organoids, taking into account 
that the developmental stage of the organoid could potentially affect the transduction efficiency 
and expression levels. This explains why serotypes, such as AAV2/5 and 2/9, that are highly 
efficient in in vivo animal studies and mature retinal explants, do not appear to transduce a large 
proportion of rods in the retinal organoids. 
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While many animal studies have been performed to evaluate the specificity and efficiency of rod- 
and cone-specific promoters, there is little data regarding their efficacy in human photoreceptors. 
Here, we tested RPE-, cone- and rod-specific promoters in human ESC-derived retinal cultures. 
Although the use of human ESC-derived cells is valuable for establishing viral vector tropism for 
AAV gene therapy in vitro as well as promoter specificity, such in vitro cultures have their 
limitations and should not be used as a sole method to aid the choice of AAV vectors to be used 
in human trials. Similar caution should be applied when using ex vivo human retinal explants. 
Measurements of transduction efficiency and biodistribution need to be examined with caution, 
as these cultures cannot fully replicate the complex environment of the eye. The concentrated 
administration, and subsequent spread of viral particles within the confined environment of the 
subretinal space cannot be replicated readily in vitro. For this reason, such in vitro studies 
should be regarded as complementary to in vivo work using animal models for the evaluation of 
viral transduction. Furthermore, it is important to note that in vitro differentiation systems do not 
currently reach later stages of development, equivalent to the adult retina. Toxicity is another 
important issue that can only be assessed in animal models, as assessments of transgene 
toxicity in cultures are limited to the cellular level. Systemic toxicity regarding immune related 
reactions to viral vectors can only be studied in vivo.  
 
In summary, we demonstrate the utility of PSC-derived retinal tissues as a test system for the 
development of gene therapy vectors. Furthermore, we have used this system to assess the 
tropism of six AAV serotypes for mouse and human photoreceptors and RPE cells and we 
demonstrate that PSC-derived cells can be used to test promoter specificity in human cells. A 
likely next step is the use of iPSC-derived retinal cells generated from patients with inherited 
retinopathies as in vitro models to test a variety of gene therapy strategies, including those 
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Figure 1. Establishing AAV tropism in mouse ESC-derived wEBs 
a. Schematic showing mouse ESC differentiation protocol into photoreceptors and viral 
labelling strategy. b-g. Representative images of wEBs showing GFP expression 
(green) under the control of a CMV promoter for the six AAV serotypes tested. h. 
Quantification of the % of cells that is GFP positive after transduction in culture. i. 
Percentage of cells that are photoreceptors (CD73+) and the percentage of cells that are 
transduced photoreceptors (GFP+/CD73+) in cultures transduced by the six AAV 
serotypes tested. Nuclei were stained with DAPI (blue). Scale bars: 100 µm (b-g). 
 
Figure 2. Testing promoter specificity in mouse ESC-derived photoreceptors 
a. Images showing co-expression of Rhodopsin (red) and GFP driven by Rhodopsin 
promoter (green) after AAV2/9 and ShH10-mediated gene delivery. b.  Images showing 
co-expression of Sopsin (red) and GFP driven by Mopsin (2.1PR) promoter (green). c. 
Percentage of GFP positive rods and cones transduced by AAV2/9 and ShH10 
serotypes. D. Percentage of live, necrotic, late apoptotic and early apoptotic rod and 
cone photoreceptors following AAV2/9 and ShH10 transduction. Nuclei were stained 
with DAPI (blue). Scale bars: 25 µm (a, b). 
 
Figure 3. Establishing AAV tropism in mouse ESC-derived RPE 
a. Schematic showing BIO treatment for mESC-derived RPE differentiation. RPE 
regions from wEBs were dissected and plated on laminin-coated plates. b. Bright field 
images showing wEBs that have been though retinal and RPE differentiation. c.  
Representative images showing the pigmented RPE regions on wEBs that have been 
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transduced by the six CMV.GFP AAV serotypes. d. Images showing virally transduced 
RPE monolayer cultures stained with Phalloidin. e. Percentage of GFP+ mESC-derived 
RPE cells transduced by the six AAV serotypes tested. Nuclei were stained with DAPI 
(blue). Scale bars: 25 µm (c,d). 
 
Figure 4. Establishing AAV tropism in human iPS-derived RPE 
a. Schematic of human pluripotent stem cells differentiation into hiPS-derived RPE. b. 
Representative image showing virally transduced hiPS-derived RPE monolayer cultures 
stained for Phalloidin. c. Percentage of GFP+ hiPS-derived RPE cells transduced by the 
by the six AAV serotypes tested. d. Percentage of hiPS-derived RPE transduced by 
ShH10 carrying either a CMV or a VMD2 promoter. e.  Percentage of live, necrotic, late 
apoptotic and early apoptotic rod and cone photoreceptors following ShH10 
transduction. Nuclei were stained with DAPI (blue). Scale bars: 25 µm (b). 
 
Figure 5. Establishing AAV tropism in human ESC-derived retinal organoids 
a. Timeline schematic of human stem cell differentiation into hESC-derived 
photoreceptors and viral labelling. b-m. Representative high magnification images of 
neuroepithelial regions transduced by six AAV serotypes at 12 weeks (b-g) and 17 
weeks (h-m) of development. No GFP+ photoreceptors were observed for any of the six 
vectors when transduced at 12 weeks, whilst GFP+ photoreceptors were present in late 
transduced cultures. n. Percentage of GFP+ cells in retinal organoids transduced at 17 
weeks of culture. Nuclei were stained with DAPI (blue). Scale bars: 25 µm (b-m). 
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Figure 6. Testing promoter specificity in human ESC-derived photoreceptors 
a. Image highlighting the morphology of ShH10.2.1.GFP transduced cells. b. 
ShH10.2.1.GFP cells co-localised with RXRγ+ cone photoreceptors (red). c. 
ShH10.2.1.GFP cells did not co-localise with RHODOPSIN+ rod photoreceptors 
(red). d. Percentage of GFP+ hESC-derived cone photoreceptors transduced by 
the AAV serotypes tested. e. M/LOPSIN+ cones (red, arrows) co-localised with 
2.1.GFP+ cones. f. SOPSIN+ cones (red, arrows) only co-localised with few 
2.1.GFP+ cones in the highly transduced ShH10. g, g’. Image of a neuroepithelia 
region showing co-localisation of GNAT1+ rod photoreceptors and 
ShH10.hRhod.GFP transduced cells. h-i’. Images of neuroepithelia regions 
transduced with ShH10.hRK.GFP vector. h’,i’. Images of a ARRESTIN3+ 
ShH10.hRK.GFP cone and GNAT1+ rod photoreceptors. Nuclei were stained 















Supplementary Figure S1. Viral transduction efficiency of six AAV serotypes on mouse 
ESC-derived wEBs  
Flow cytometry gate strategy for mouse ESC-derived wEB. a. Representative plot showing a 
negative control, non-virus transduced wEB, with GFP gate. b. Representative plots showing the 
percentage of GFP+ cells from each virus tested. c. Table showing the % GFP cells shown in c 
with corresponding MFI. d. Percentage of live, necrotic, late apoptotic and early apoptotic cells 
















Supplementary Figure S2. Viral transduction efficiency of six AAV2 serotypes on mouse 
ESC-derived photoreceptors  
Flow cytometry gate strategy of a mouse ESC-derived wEB. a. Representative plot of a non-
virus transduced EB showing gates for GFP+ (bottom right panel), CD73+ (top left panel) and 
CD73+/GFP+ (top right panel).  b. Representative plot of a non-virus transduced EB stained for 
photoreceptor marker CD73. c. Representative plots showing the percentage of GFP+ cells 
(bottom right panel), CD73+ photoreceptors and double positive CD73+/GFP+ photoreceptors 








Supplementary Figure S3. Intravitreal injections of AAV vectors in wild type mice. 
a-f. Images of young adult wild type retina intravitreally injected at P5.5-P6.5 with a range of 
AAV serotypes. Each AAV vector shows different transduction efficiency targeting interneurons 
in the INL. AAV2/2 and ShH10 showed widespread expression of GFP, with the later 



















Supplementary Figure 4. Establishing ShH10 tropism in mouse ESC-derived cells 
a. Image showing ShH10.CMV.GFP (green) transduced neuroepithelia region and co-
localization with CRALBP+ (red) Muller cells. b. Image showing ShH10.CMV.GFP (green) 
transduced neuroepithelia region and co-localization with Recoverin+ (red) photoreceptor cells. 









Supplementary Figure S5. Transduction specificity of AAV2/8.PR2.1.GFP in the adult 
wildtype retina 
a. Image of a wild type retina subretinally injected with an AAV2/8.PR.2.1.GFP virus showing co-
localisation of GFP with S-opsin cones (red).  b.  Image of the same wild type retina showing co-














Supplementary Figure S6. Viral transduction efficiency of ShH10 and AAV2/9 serotypes 
on mouse ESC-derived rod and cone photoreceptors  
Flow cytometry gate strategy of a mouse ESC-derived wEB a. Representative plot showing a 
dissociated GFP negative non-virus transduced EB gated for GFP. b,b’. Gate showing the 
percentage of GFP+ cells from ShH10 and AAV2/9 Rhodopsin.GFP+ rod photoreceptors. c,c’. 















Supplementary Figure S7. Viral transduction efficiency of human ESC-derived 
photoreceptors 
a. Low magnification image showing an AAV2/8.CMV.GFP transduced retinal organoid. 
RECOVERIN+ (red) photoreceptors neuroepithelia is negative for GFP+. Flow cytometry gate 
strategy of a human ESC-derived optic vesicle. b. Representative plot showing a dissociated 
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organoids stained for Sytox Blue dead cell stain used to exclude dead cells and cellular debris 
and identify the live cell population. c,c’. Plot showing the exclusion of cellular aggregates to 
isolate single cells. d. Plot depicting the relative size and granularity of single, live cells. e. 
Histograms showing anon-virus treated control and the percentage of GFP+ cone 
photoreceptors (2.1.GFP) for each of the viruses tested. Nuclei were stained with DAPI (blue). 







Supplementary Table 2. Antibodies used for immunohistochemistry 
Antigen Host species Concentration used Supplier 
Cralbp mouse 1 in 100 Abcam (15051) 
Mitf mouse 1 in 200 Millipore (MAB3747) 
Recoverin rabbit 1 in 1000 Millipore/Merck (AB5585) 
Rhodopsin mouse 1 in 1000 Sigma (O4886) 
Rxrγ rabbit 1 in 200 Abcam (ab15518) 
Sopsin rabbit 1 in 200 Millipore (AB5407) 
Mopsin rabbit 1 in 200 Millipore (AB5405) 
Gnat1  rabbit 1 in 1000 Santa Cruz  
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